Return To The Previous Page
Buy a Package
Number Of Visible Items Remaining : 3 Item

Effect of immunosuppressive agents on vaccine immunogenicity

Effect of immunosuppressive agents on vaccine immunogenicity
  Methotrexate TNF-alpha inhibitors Anti-CD20 antibodies
(eg, rituximab)
CTLA-4 inhibitors
(eg, abatacept)
Janus kinase inhibitors
(eg, tofacitinib)
Anti-IL-6 antibodies
(eg, tocilizumab)
Anti-IL-12/23 inhibitors Anti-IL-17 inhibitors
Pneumococcal vaccine Decrease Minimal effect Substantial decrease Decrease Decrease Minimal effect Minimal effect Minimal effect
Seasonal influenza vaccine Decrease Minimal effect Substantial decrease Decrease Minimal effect Minimal effect Minimal effect Minimal effect
Hepatitis B virus vaccine Unknown Decrease Unknown Unknown Unknown Unknown Unknown Unknown
Tetanus vaccine Decrease Minimal effect Decrease

SQ: minimal effect

IV: decrease

Tofacitinib: minimal effect

Baricitinib: decrease
Minimal effect Minimal effect Minimal effect
SARS-CoV-2 vaccine Decrease Minimal effect Substantial decrease Decrease Decrease Minimal effect Minimal effect Minimal effect
Vaccinations are expected to confer adequate protection for most patients with rheumatic diseases who are using conventional synthetic DMARDs, most biologics, or glucocorticoids; however, the immune response to some vaccines may be blunted. The degree to which the immune response may be altered by these medications varies based on the specific immunosuppressive drug regimen, vaccines used, and other patient-specific factors. The effect of immunosuppressive agents on the immune responses to vaccines other than those listed above has not been well studied. Refer to the UpToDate text for additional detail.
CTLA: cytotoxic T lymphocyte antigen; DMARDs: disease-modifying antirheumatic drugs; IL: interleukin; IV: intravenous; SQ: subcutaneous; TNF: tumor necrosis factor.
Data from:
  1. Subesinghe S, Bechman K, Rutherford AI, et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J Rheumatol 2018; 45:733.
  2. Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80:1255.
Graphic 119666 Version 3.0

Do you want to add Medilib to your home screen?